Analysis of novel meningococcal vaccine formulations

References

• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369(9580):2196-210; PMID:17604802; https://doi.org/10.1016/S0140-6736(07)61016-2
   PubMed Web of Science ®Google Scholar
• Zughaier SM. Neisseria meningitidis capsular polysaccharides induce inflammatory responses via TLR2 and TLR4-MD-2. J Leukoc Biol 2011; 89(3):469-80; PMID:21191086; https://doi.org/10.1189/jlb.0610369
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health 2016; 59(2 Suppl):S3-S11; PMID:27449148; https://doi.org/10.1016/j.jadohealth.2016.04.012
   PubMed Web of Science ®Google Scholar
• Piccini G, Torelli A, Gianchecchi E, Piccirella S, Montomoli E. Fighting Neisseria meningitidis: Past and current vaccination strategies. Expert Rev Vaccines 2016; 15(11):1393-407; PMID:27158988; https://doi.org/10.1080/14760584.2016.1187068
   PubMed Web of Science ®Google Scholar
• Dakar discussion group on priorities for research on epidemic meningococcal disease in A, Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, Caugant D, Clark T, Collard JM, et al. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine 2013; 31(11):1453-7; PMID:23273967; https://doi.org/10.1016/j.vaccine.2012.12.035
   PubMed Web of Science ®Google Scholar
• Lee CH, Kuo WC, Beri S, Kapre S, Joshi JS, Bouveret N, LaForce FM, Frasch CE. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009; 27(5):726-32; PMID:19063929; https://doi.org/10.1016/j.vaccine.2008.11.065
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013; 56(3):354-63; PMID:23087396; https://doi.org/10.1093/cid/cis892
   PubMed Web of Science ®Google Scholar
• Gala RP, D'Souza M, Zughaier SM. Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine. Vaccine 2016; 34(28):3260-7; PMID:27177946; https://doi.org/10.1016/j.vaccine.2016.05.010
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther 2016; 5(2):89-112; PMID:27086142; https://doi.org/10.1007/s40121-016-0107-0
   PubMed Web of Science ®Google Scholar
• Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard AJ, Turner DP, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial. Lancet 2014; 384(9960):2123-31; PMID:25145775; https://doi.org/10.1016/S0140-6736(14)60842-4
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, Percell S, Odrljin T, Dull PM, Smolenov I. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J 2014; 33(11):1169-76; PMID:24911896; https://doi.org/10.1097/INF.0000000000000438
   PubMed Web of Science ®Google Scholar
• Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, Schmidt DS, Johnson SE, Milton A, Rajam G, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014; 15(2):195-204; PMID:24336226; https://doi.org/10.1038/ni.2789
   PubMed Web of Science ®Google Scholar
• Ubale RV, Gala RP, Zughaier SM, D'Souza MJ. Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles. AAPS J 2014; 16(5):986-93; PMID:24981893; https://doi.org/10.1208/s12248-014-9635-2
   PubMed Web of Science ®Google Scholar
• Ubale RV, D'Souza MJ, Infield DT, McCarty NA, Zughaier SM. Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition. J Microencapsul 2013; 30(1):28-41; PMID:22657751; https://doi.org/10.3109/02652048.2012.692402
   PubMed Web of Science ®Google Scholar
• Collard JM, Issaka B, Zaneidou M, Hugonnet S, Nicolas P, Taha MK, Greenwood B, Jusot JF. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis 2013; 13:576; PMID:24313998; https://doi.org/10.1186/1471-2334-13-576
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, Tenebray B, Kairo KK, Giorgini D, Chanteau S. Meningococcal meningitis: Unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44(5):657-63; PMID:17278055; https://doi.org/10.1086/511646
   PubMed Web of Science ®Google Scholar
• Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine. Vaccine 2013; 31(27):2852-61; PMID:23623866; https://doi.org/10.1016/j.vaccine.2013.04.036
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Ba AK, Ouedraogo AS, Sanou I, Ouedraogo R, Sangare L, Diomandé F, Kandolo D, Saga IM, Misegades L, et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect Dis 2014; 14:663; PMID:25472422; https://doi.org/10.1186/s12879-014-0663-4
   PubMed Web of Science ®Google Scholar
• Ba AK, Sanou I, Kristiansen PA, Sangare L, Ouedraogo R, Ouattara K, Kienou M, Tiendrebeogo S, Tranchot J. Evolution of meningococcal carriage in serogroups X and Y before introduction of MenAfriVac in the health district of Kaya, Burkina Faso. BMC Infect Dis 2014; 14:546; PMID:25311771; https://doi.org/10.1186/s12879-014-0546-8
   PubMed Web of Science ®Google Scholar
• Lamelas A, Harris SR, Roltgen K, Dangy JP, Hauser J, Kingsley RA, Connor TR, Sie A, Hodgson A, Dougan G, et al. Emergence of a new epidemic Neisseria meningitidis serogroup A Clone in the African meningitis belt: High-resolution picture of genomic changes that mediate immune evasion. MBio 2014; 5(5):e01974-14; PMID:25336458; https://doi.org/10.1128/mBio.01974-14
   PubMed Web of Science ®Google Scholar
• Vandebriel R, Hoefnagel MM. Dendritic cell-based in vitro assays for vaccine immunogenicity. Hum Vaccin Immunother 2012; 8(9):1323-5; PMID:22951585; https://doi.org/10.4161/hv.21350
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010; 28(9):2122-9; PMID:20044056; https://doi.org/10.1016/j.vaccine.2009.12.027
   PubMed Web of Science ®Google Scholar
• Zughaier SM, Svoboda P, Pohl J, Stephens DS, Shafer WM. The human host defense peptide LL-37 interacts with Neisseria meningitidis capsular polysaccharides and inhibits inflammatory mediators release. PLoS One 2010; 5(10):e13627; PMID:21049021; https://doi.org/10.1371/journal.pone.0013627
   PubMed Web of Science ®Google Scholar
• Zughaier SM, Shafer WM, Stephens DS. Antimicrobial peptides and endotoxin inhibit cytokine and nitric oxide release but amplify respiratory burst response in human and murine macrophages. Cell Microbiol 2005; 7(9):1251-62; PMID:16098213; https://doi.org/10.1111/j.1462-5822.2005.00549.x
   PubMed Web of Science ®Google Scholar
• Prokopowicz ZM, Arce F, Biedron R, Chiang CL, Ciszek M, Katz DR, Nowakowska M, Zapotoczny S, Marcinkiewicz J, Chain BM. Hypochlorous acid: A natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J Immunol 2010; 184(2):824-35; PMID:20018624; https://doi.org/10.4049/jimmunol.0902606
   PubMed Web of Science ®Google Scholar
• Kensil CR, Mo AX, Truneh A. Current vaccine adjuvants: An overview of a diverse class. Front Biosci 2004; 9:2972-88; PMID:15353330; https://doi.org/10.2741/1452
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 2016; 12(1):1-222; PMID:26799652; https://doi.org/10.1080/15548627.2015.1100356
   PubMed Web of Science ®Google Scholar
• Crotzer VL, Blum JS. Autophagy and adaptive immunity. Immunology 2010; 131(1):9-17; PMID:20586810; https://doi.org/10.1111/j.1365-2567.2010.03321.x
   PubMed Web of Science ®Google Scholar
• Ireland JM, Unanue ER. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J Exp Med 2011; 208(13):2625-32; PMID:22162830; https://doi.org/10.1084/jem.20110640
   PubMed Web of Science ®Google Scholar
• Zughaier SM, Kandler JL, Balthazar JT, Shafer WM. Phosphoethanolamine modification of Neisseria gonorrhoeae lipid A reduces autophagy flux in macrophages. PLoS One 2015; 10(12):e0144347; PMID:26641098; https://doi.org/10.1371/journal.pone.0144347
   PubMed Web of Science ®Google Scholar
• Garlapati S, Facci M, Polewicz M, Strom S, Babiuk LA, Mutwiri G, Hancock RE, Elliott MR, Gerdts V. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet Immunol Immunopathol 2009; 128(1-3):184-91; PMID:19042032; https://doi.org/10.1016/j.vetimm.2008.10.298
   PubMed Web of Science ®Google Scholar
• Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009; 27(Suppl 2):B117-25; PMID:19477054; https://doi.org/10.1016/j.vaccine.2009.04.066
   PubMed Web of Science ®Google Scholar
• Siegrist C-A. Vaccine immunology. Vaccines 2013; 6th Edition: chap. 2, 17-36.
   PubMed Web of Science ®Google Scholar
• Carollo M, Palazzo R, Bianco M, Smits K, Mascart F, Ausiello CM. Antigen-specific responses assessment for the evaluation of Bordetella pertussis T cell immunity in humans. Vaccine 2012; 30(9):1667-74; PMID:22230582; https://doi.org/10.1016/j.vaccine.2011.12.104
   PubMed Web of Science ®Google Scholar
• Monari C, Paganelli F, Bistoni F, Kozel TR, Vecchiarelli A. Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cell Microbiol 2008; 10(10):2129-37; PMID:18647312; https://doi.org/10.1111/j.1462-5822.2008.01196.x
   PubMed Web of Science ®Google Scholar
• Bossaller L, Chiang PI, Schmidt-Lauber C, Ganesan S, Kaiser WJ, Rathinam VA, Mocarski ES, Subramanian D, Green DR, Silverman N, et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1beta and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol 2012; 189(12):5508-12; PMID:23144495; https://doi.org/10.4049/jimmunol.1202121
   PubMed Web of Science ®Google Scholar
• Pericolini E, Cenci E, Monari C, De Jesus M, Bistoni F, Casadevall A, Vecchiarelli A. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol 2006; 8(2):267-75; PMID:16441437; https://doi.org/10.1111/j.1462-5822.2005.00619.x
   PubMed Web of Science ®Google Scholar
• Vasconcelos JR, Bruna-Romero O, Araujo AF, Dominguez MR, Ersching J, de Alencar BC, Machado AV, Gazzinelli RT, Bortoluci KR, Amarante-Mendes GP, et al. Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: Reversal by adenoviral vaccine. PLoS Pathog 2012; 8(5):e1002699; PMID:22615561; https://doi.org/10.1371/journal.ppat.1002699
   PubMed Web of Science ®Google Scholar
• Guillermo LV, Silva EM, Ribeiro-Gomes FL, De Meis J, Pereira WF, Yagita H, DosReis GA, Lopes MF. The Fas death pathway controls coordinated expansions of type 1 CD8 and type 2 CD4 T cells in Trypanosoma cruzi infection. J Leukoc Biol 2007; 81(4):942-51; PMID:17261545; https://doi.org/10.1189/jlb.1006643
   PubMed Web of Science ®Google Scholar
• Zuniga E, Motran CC, Montes CL, Yagita H, Gruppi A. Trypanosoma cruzi infection selectively renders parasite-specific IgG+ B lymphocytes susceptible to Fas/Fas ligand-mediated fratricide. J Immunol 2002; 168(8):3965-73; PMID:11937553; https://doi.org/10.4049/jimmunol.168.8.3965
   PubMed Web of Science ®Google Scholar
• Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165(Suppl 1):S49-52; PMID:1588177; https://doi.org/10.1093/infdis/165-Supplement_1-S49
   PubMed Web of Science ®Google Scholar
• Oliveira TG, Milani SR, Travassos LR. Polyclonal B-cell activation by Neisseria meningitidis capsular polysaccharides elicit antibodies protective against Trypanosoma cruzi infection in vitro. J Clin Lab Anal 1996; 10(4):220-8; PMID:8811466; https://doi.org/10.1002/(SICI)1098-2825(1996)10:4<220::AID-JCLA8>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar
• Hostmann A, Jacobi AM, Mei H, Hiepe F, Dorner T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 2008; 17(12):1064-9; PMID:19029273; https://doi.org/10.1177/0961203308095138
   PubMed Web of Science ®Google Scholar
• Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58(6):1762-73; PMID:18512812; https://doi.org/10.1002/art.23498
   PubMed Web of Science ®Google Scholar